2,176 reports of this reaction
3.2% of all TESTOSTERONE reports
#4 most reported adverse reaction
DEEP VEIN THROMBOSIS is the #4 most commonly reported adverse reaction for TESTOSTERONE, manufactured by ASCEND Therapeutics U.S., LLC. There are 2,176 FDA adverse event reports linking TESTOSTERONE to DEEP VEIN THROMBOSIS. This represents approximately 3.2% of all 67,752 adverse event reports for this drug.
TESTOSTERONE has an overall safety score of 85 out of 100. Patients taking TESTOSTERONE who experience deep vein thrombosis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEEP VEIN THROMBOSIS is moderately reported among TESTOSTERONE users, representing a notable but not dominant share of adverse events.
In addition to deep vein thrombosis, the following adverse reactions have been reported for TESTOSTERONE:
The following drugs have also been linked to deep vein thrombosis in FDA adverse event reports:
DEEP VEIN THROMBOSIS has been reported as an adverse event in 2,176 FDA reports for TESTOSTERONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEEP VEIN THROMBOSIS accounts for approximately 3.2% of all adverse event reports for TESTOSTERONE, making it a notable side effect.
If you experience deep vein thrombosis while taking TESTOSTERONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.